Harbour BioMed signed a discovery and development collaboration with Bristol Myers Squibb to advance multispecific antibody therapeutics, securing approximately $90 million upfront and potential development and commercial milestones that could top $1.035 billion. The deal leverages Harbour’s Harbour Mice platform and Hu‑matrix AI tools to generate fully human multispecific antibodies. Harbour said the agreement enables early clinical acceleration including potential early trials in China, citing prior partnerships and platform investments that boosted discovery throughput. CEO Jingsong Wang framed the collaboration as a way to “accelerate programs through early clinical trials in China.” The transaction underscores continued big‑pharma interest in multispecific modalities and AI‑driven antibody discovery, and it provides Harbour with near‑term non‑dilutive capital to advance lead programs.